<DOC>
	<DOCNO>NCT03078400</DOCNO>
	<brief_summary>Up 18 woman ovarian cancer administer two injection SPL-108 daily combination weekly dose Paclitaxel . They monitor safety efficacy 6 month , disease progression unacceptable toxicity .</brief_summary>
	<brief_title>Safety Efficacy Study Daily SPL-108 Injections In Conjunction With Paclitaxel Women With Ovarian Cancer</brief_title>
	<detailed_description>This open-label 2-arm trial . Eligible subject screen enrol sequentially 1 2 Arms : Arm I : N=6 12 subject , Safety Phase - Cohort 1 SPL-108 x 1 injection daily + 80 mg/m2 PTX weekly Days 1 , 8 , 15 28 day cycle - Cohort 2 SPL-108 BID + 80 mg/m2 PTX weekly Days 1 , 8 , 15 28 day cycle For Arm I , least 1 week elapse Dose 1 subject . In Cohort 1 , 3 subject enrol : 1 dose-limiting toxicity ( DLT ) occur , 3 subject add dose level ; 0/3 1/6 DLTs occur , Cohort 2 initiate enrolling subject ; 2 DLTs occur dose level , subject enrol Cohort 2 trial terminate . In Cohort 2 , 3 subject enrol : 1 DLT occurs , 3 subject add dose level ; 0/3 1/6 DLTs occur , Arm II initiate enrol subject SPL-108 BID dose ; 2 DLTs occur , Arm II initiate enrol subject SPL-108 dose one time day . Arm II : N=up 12 , Exploratory Expansion Phase • Cohort 3 : SPL-108 daily dose ( determined Arm I ) + 80 mg/m2 PTX weekly Days 1 , 8 , 15 28 day cycle . A Safety Committee meet end Arm I Cohort well periodically review safety data make recommendation trial progression . The primary efficacy outcome , Response Evaluation Criteria Solid Tumors Committee ( RECIST 1.1 ) criterion , assess Day 15 Cycles 2 , 4 , 6 .</detailed_description>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>1 . Females ≥18 year age 2 . Platinumresistant recurrent metastatic epithelial ovarian carcinoma 3 . Positivity CD44 assay define strong ( +++ ) moderate ( ++ ) stain 20 % tumor tissue obtain biopsy paracentesis within 60 day prior Cycle 1 Day 1 4 . Status post firstline therapy definitive surgery ( provide tissue pathologic diagnosis ) chemotherapy 5 . Original diagnosis confirm histopathologic review primary tumor slide expert pathologist Principal Investigator 's institution 6 . Disease progress recur less 6 month platinumbased chemotherapy point subject 's course . 7 . No 2 prior regimen cytotoxic chemotherapy , least one platinumbased 8 . Measurable disease RECIST 1.1 criterion 9 . Eastern Cooperative Oncology Group performance status ( ECOG PS ) 0 , 1 , 2 10 . Women childbearing potential partner must use effective contraception study 3 month last dose 11 . Life expectancy least 6 month 12 . Able understand comply study procedure , understand risk involve study , provide write informed consent first studyspecific procedure 1 . Treatment cytotoxic chemotherapy malignancy ovarian cancer within past 5 year 2 . Fewer 30 day Cycle 1 Day 1 since prior chemotherapy ( le 42 day case mitomycin nitrosourea ) 3 . Fewer 30 day Cycle 1 Day 1 since administration hormonal biological antineoplastic agent 4 . Concomitant use cytotoxic cytostatic drug PTX 5 . Abnormal clinical laboratory value within 14 day prior initiation dosing , indicate : Hemoglobin level &lt; 9.0 gm/L Platelet count &lt; 100,000/mm3 Granulocyte count &lt; 1500/mm3 Serum creatinine level ≥2.5 mg/dL ( 221 μmol/L ) Liver aminotransferase level great 3 time laboratory 's upper limit normal ( great 5 time laboratory 's upper limit normal liver know involved tumor ) 6 . Contraindication use PTX 7 . Pregnancy breastfeed time Screening throughout study . 8 . Active , uncontrolled infection 9 . Participation another investigational drug trial concurrently within 30 day Cycle 1 Day 1 , vaccine trial within 90 day Cycle 1 Day 1 10 . Significant acute chronic medical psychiatric illness , judgment Investigator , could compromise subject safety , limit subject 's ability complete trial , and/or compromise objective trial</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>